A prodrug form of rhein
Related Products
Active Metabolite(s)
17345Rhein
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Diacerein

Item No. 11710

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid
CAS Number
13739-02-1
Synonyms
  • DAR
  • Diacerhein
  • 4,5-Diacetylrhein
  • SF 277
Molecular Formula
C19H12O8
Formula Weight
368.3
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMSO: 15 mg/mlDMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml
λmax
216, 255, 337 nm
SMILES
OC(C(C=C1OC(C)=O)=CC2=C1C(C3=C(C2=O)C=CC=C3OC(C)=O)=O)=O
InChi Code
InChI=1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
InChi Key
TYNLGDBUJLVSMA-UHFFFAOYSA-N
Origin
Plant/Aloe barbadensis
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $49

    Add

    50 mg

    $93

    Add

    100 mg

    $160

    Add

    250 mg

    $329

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Diacerein is a prodrug form of the anthraquinone derivative rhein (Item No. 17345).1 It inhibits RANKL- and IL-1β-induced differentiation of RAW 264.7 cells into osteoclasts when used at a concentration of 20 µg/ml.2 Diacerein (20 µg/ml) reduces levels of interleukin-1β-converting enzyme (ICE), also known as caspase-1, as well as IL-1β, and IL-18 in the superficial zone of human osteoarthritic cartilage explants.3 It decreases carrageenan-, dextran-, or zymosan-induced paw edema in rats when administered at a dose of 100 mg/kg.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Cai, J., Duan, Y., Yu, J., et al. Bone-targeting glycol and NSAIDS ester prodrugs of rhein: Synthesis, hydroxyapatite affinity, stability, anti-inflammatory, ulcerogenicity index and pharmacokinetics studies. Eur. J. Med. Chem. 55, 409-419 (2012).

    2. Boileau, C., Tat, S.K., Pelletier, J.P., et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: A possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res. Ther. 10(3), R71 (2008).

    3. Moldovan, F., Pelletier, J.P., Jolicoeur, F.C., et al. Diacerhein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage. Osteoarthritis Cartilage 8(3), 186-196 (2000).

    4. Tamura, T., Shirai, T., Kosaka, N., et al. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur. J. Pharmacol. 448(1), 81-87 (2002).